Leading international pharmaceutical outsourcing services provider PCI Pharma Services has completed the installation and validation of a new Serialisation suite at its recently acquired site in Ireland, EU.
The announcement demonstrates PCI’s continued investment in and expansion of its market-leading Serialisation capability. This latest installation increases PCI’s Serialisation capability to support clients in advance of meeting the implementation dates of the European Falsified Medicines Directive (EU FMD).
The highly flexible technology delivers machine and human-readable coding, tamper evident solutions and Bollini labelling – which in turn is linked to a case loading and aggregation station, with a final aggregation station connecting cases to pallet. PCI is a strong supporter of the advanced use of aggregation to realise the significant benefits in packaging operations, as well as the broader pharmaceutical supply chain.
PCI’s site near Dublin already offers excellence in commercial packaging services for customers globally, and this new Serialisation technology further strengthens PCI’s offering across Europe. This investment in PCI’s Dublin facility is part of a significant global initiative from PCI to develop its Serialisation services across its global network, plans that will triple its overall Serialisation capacity.
Commenting on this latest investment, Ian Parsonage, PCI’s Senior Director of Global Serialisation stated: “This is an important addition to the site’s capabilities and PCI as a whole. Ensuring supply chain integrity and patient safety is of critical importance. We pride ourselves on real-life experience and expertise in this area and our commitment through such significant strategic investment continues to demonstrate and deliver a truly industry-leading solution for our customers. Being able to offer this fully flexible service and work in partnership with our customers from our site in the EU is essential ahead of the timelines for compliance with the EU FMD. Our customers also enjoy the benefits of a single B2B data exchange providing access to each site within our integrated global supply network. Having Dublin now commercial ready is one more seamless access point for supporting their global supply needs.”
Since announcing its global Serialisation investment in February 2017, PCI has rolled out a series of developments at its sites in the US and EU as part of the ongoing program across its global supply network. The investment includes providing best-in-class equipment; a flexible and seamless data exchange; and skilled staff teams with real Serialisation expertise.
PCI’s Dublin site is one of the most recent additions to the organisation's global network following the acquisition of Millmount Healthcare in 2017. As part of the overall strategy, the four sites in Ireland have been subject to a full rebranding exercise to become fully integrated into PCI Pharma Services. This investment in state-of-the-art Serialisation technology at the Dublin site demonstrates PCI’s commitment to offering a truly global solution from its EU base.